F18-FDG HEART UPTAKE IN ONCOLOGIC PET STUDIES.

REFERENCES

1. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J and Phelps ME. PET in Oncology: Will it replace the Other Modalities?. Semin Nucl Med 1997: 27: 94-106.
2. Bar-Shalom R, Valdivia AY and Blaufox MD. PET Imaging in Oncology. Semin Nucl Med 2000; 30: 150-185.
3. Opie LH, Hesse B. Radionuclide tracers in the evaluation of resting myocardial ischaemia and viability. Eur J Nucl Med 1999;24:1183-93.
4. Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose. J Nucl Cardiol 1994; 1: s4-14.
5. Choi Y, Brunkin RC Hawkins RA, Huang SC, Buxton DB, Hoh CK, Phelps ME, Schelbert HR.. Factors affecting myocardial 2-F-18 fluoro-2-deoxi-D-gluucose uptake in positron emission tomograpphy studies of normal humans. Eur J Nucl Med 1993;20:308-318
6. Lindholm P Minn H et al. Influence of blood glucose concentration in FDG uptake in cancer-A PET study. J Nucl Med 1993;34:1-6
7. Zasadny KR et al. SUV of normal tissues at PET with F-18 FDG: variations with body weight and a method for correction. Radiology 1993; 189: 847-50.
8. Minn H et al. F-18 FDG uptake in tumors: kinetic vs steady-state methods with reference to plasma insulin. J Comp Assist Tomography 1993; 17: 115-23.
9. Torizuka T et al. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997; 38: 382-6.
10. Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH and Visser CA. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. Eur J Nucl Med 1997; 24: 35-41.

Summary | Introduction | Materials and Methods | Results | Discussion | References | Complete Versión | Article Home